Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12605349 | 1.00 | SIGMAR1 (0.54) | SIGMAR1HSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL29299530 | 0.93 | HSD17B10 (0.45) | SIGMAR1HSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL29299531 | 0.93 | HSD17B10 (0.45) | SIGMAR1HSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL16582319 | 0.93 | HSD17B10 (0.45) | SIGMAR1HSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL19361138 | 0.93 | SIGMAR1 (0.56) | SIGMAR1HSD17B10KMT2AALDH1A1TSHR | |
| SCHEMBL14312080 | 0.93 | SIGMAR1 (0.56) | SIGMAR1HSD17B10KMT2AALDH1A1TSHR | |
| SCHEMBL12605217 | 0.93 | SIGMAR1 (0.56) | SIGMAR1HSD17B10KMT2AALDH1A1TSHR | |
| SCHEMBL16855794 | 0.93 | SIGMAR1 (0.56) | SIGMAR1HSD17B10KMT2AALDH1A1TSHR | |
| SCHEMBL20686921 | 0.93 | HSD17B10 (0.45) | SIGMAR1HSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL14728651 | 0.93 | SIGMAR1 (0.56) | SIGMAR1HSD17B10KMT2AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550704-B2 | Method for synthesizing radiopharmaceuticals using a cartridge | FUTURECHEM CO., LTD. (KR) | 2017-01-24 | — | — | US | disclosed |
| US-20150232392-A1 | METHOD FOR SYNTHESIZING RADIOPHARMACEUTICALS USING A CARTRIDGE | FUTURECHEM CO., LTD. (KR) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232392-A1 | METHOD FOR SYNTHESIZING RADIOPHARMACEUTICALS USING A CARTRIDGE | ADCYAP1R1, PAICS, SSTR5 | SIGMAR1 1612/4885HSD17B10 3482/4885KMT2A 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.